Page 6 - Affimed News Today

HC Wainwright reissued their buy rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s stock. AFMD has been the topic of several other research reports. SVB Leerink decreased their price objective on Affimed from […]

Affimed (NASDAQ:AFMD – Get Rating) had its price objective cut by equities researchers at Stifel Nicolaus from $2.00 to $1.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside […]

Investment Analysts’ downgrades for Friday, March 24th: Affimed (NASDAQ:AFMD) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Berkshire Hills Bancorp (NYSE:BHLB) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Bruker (NASDAQ:BRKR) was downgraded by analysts at StockNews.com from a strong-buy rating to a […]

Stock Analysts’ price target changes for Friday, March 24th: AirBoss of America (OTCMKTS:ABSSF) had its price target lowered by TD Securities from C$14.00 to C$11.50. Accolade (NASDAQ:ACCD) had its target price raised by Truist Financial Co. to $17.00. Accenture (NYSE:ACN) had its price target boosted by Citigroup Inc. from $300.00 to $310.00. Citigroup Inc. currently […]

HEIDELBERG, Germany, Aug. 04, 2022 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will... | August 4, 2022

Affimed (NASDAQ:AFMD – Get Rating)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.04 and traded as high as $3.23. Affimed shares last traded at $3.11, with a volume of 994,125 shares trading hands. Several equities research analysts have recently […]

Shares of Affimed (NASDAQ:AFMD – Get Rating) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among […]

Affimed (NASDAQ:AFMD – Get Rating) and AbCellera Biologics (NASDAQ:ABCL – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation. Volatility & Risk Affimed has a beta of 2.51, indicating that […]

Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 6,200,000 shares, a decline of 18.2% from the April 30th total of 7,580,000 shares. Based on an average daily volume of 1,880,000 shares, the days-to-cover ratio […]

Affimed (NASDAQ:AFMD – Get Rating) will be releasing its earnings data before the market opens on Wednesday, June 1st. Analysts expect Affimed to post earnings of ($0.18) per share for the quarter. Affimed (NASDAQ:AFMD – Get Rating) last announced its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) earnings per share […]